This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reinhold, W. C. Articles by Weinstein, J. N. Search for Related Content PubMed PubMed Citation Articles by Reinhold, W. C. Articles by Weinstein, J. N.

Apoptotic Susceptibility of Cancer Cells Selected for Camptothecin Resistance

Gene Expression Profiling, Functional Analysis, and Molecular Interaction Mapping

Laboratory of Molecular Pharmacology [W. C. R., H. K-M., K. W. K., A. K. M., S. L., J. A., Y. U., Y. P., J. N. W.] and Genetics Branch [A. R., K. S., I. R. K.], Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892; University of Miami, Coral Gables, Florida 33146 [P. P.]; Advanced Technology Center, National Cancer Institute, Gaithersburg, Maryland 20874 [L. M., E. L.]; and First Department of Internal Medicine, Fukui Medical University, Fukui 910-1193, Japan [Y. U.]

To study the molecular mechanisms by which drug resistance develops, we compared DU145 humanprostate cancer cells with a subline selected for resistance to camptothecin.Differences in gene expression level were assessed by hybridizing the two cell types against each other using quadruplicate "Oncochip" cDNA microarrays that included 1648 cancer-related genes. Expression levels differing by a factor of >1.5 were detected for 181 of the genes. These differences were judged statistically reliable on the basis of a stratum-adjusted Kruskal-Wallis test, after taking into account a dye-dependent variable. The 181 expression-altered genes included a larger than expected number of the "apoptosis-related" genes (P = 0.04). To assess whether this observation reflected a generalized resistance of RCO.1 to apoptosis, we exposed the cells to a range of stresses (cisplatin, staurosporine, UV, ionizing radiation, and serum starvation) and found greatly reduced apoptotic responses for RC0.1 (relative to DU145) using flow cytometric Annexin V and terminal deoxynucleotidyl transferase-mediated nick end labeling assays. We next examined the apoptosis-related genes in the context of a molecular interaction map and found expression differences in the direction "expected" on the basis of the apoptosis-resistance of RC0.1 for BAD, caspase-6, and genes that signal via the Akt pathway. Exposure of the cells to wortmannin, an inhibitor of the Akt effector phosphatidylinositol 3-kinase, provided functional support for involvement of the Akt pathway. However, closer examination of the molecular interaction map revealed a paradox: many of the expression differences observed for apoptosis-related genes were in the direction "contrary" to that expected given the resistance of RC0.1. The map indicated that most of these unexpected expression differences were associated with genes involved in the nuclear factor B and transforming growth factor ß pathways. Overall, the patterns that emerged suggested a two-step model for the selection process that led to resistance in RC0.1 cells. The first hypothesized step would involve a decrease in apoptotic susceptibility through changes in the apoptosis-control machinery associated with the Bcl-2 and caspase gene families, and also in antiapoptotic pathways operating through Akt/PKB. The second step would involve changes in multifunctional upstream genes (including some genes in the nuclear factor B and transforming growth factor ß pathways) that can facilitate apoptosis but that would also tend to contribute to cell proliferation in the presence of drug. Thus, we propose that a downstream blockade of apoptosis was "permissive" for the selection of upstream pathway changes that would otherwise have induced apoptosis. This model is analogous to one suggested previously for the relationship between oncogene function and apoptosis in carcinogenesis.

This article has been cited by other articles:

				O. Sordet, A. Goldman, C. Redon, S. Solier, V. A. Rao, and Y. Pommier Topoisomerase I Requirement for Death Receptor-induced Apoptotic Nuclear Fission J. Biol. Chem., August 22, 2008; 283(34): 23200 - 23208. [Abstract] [Full Text] [PDF]

				O. N. Ikediobi, M. Reimers, S. Durinck, P. E. Blower, A. P. Futreal, M. R. Stratton, and J. N. Weinstein In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation Mol. Cancer Ther., June 1, 2008; 7(6): 1337 - 1346. [Abstract] [Full Text] [PDF]

				J. N. Weinstein Spotlight on molecular profiling: "Integromic" analysis of the NCI-60 cancer cell lines Mol. Cancer Ther., November 1, 2006; 5(11): 2601 - 2605. [Full Text] [PDF]

				L. A. Hazlehurst, R. F. Argilagos, M. Emmons, D. Boulware, C. A. Beam, D. M. Sullivan, and W. S. Dalton Cell Adhesion to Fibronectin (CAM-DR) Influences Acquired Mitoxantrone Resistance in U937 Cells Cancer Res., February 15, 2006; 66(4): 2338 - 2345. [Abstract] [Full Text] [PDF]

				J. M. Rodriguez-Pena, R. M. Perez-Diaz, S. Alvarez, C. Bermejo, R. Garcia, C. Santiago, C. Nombela, and J. Arroyo The 'yeast cell wall chip' - a tool to analyse the regulation of cell wall biogenesis in Saccharomyces cerevisiae Microbiology, July 1, 2005; 151(7): 2241 - 2249. [Abstract] [Full Text] [PDF]

				J.-P. Annereau, G. Szakacs, C. J. Tucker, A. Arciello, C. Cardarelli, J. Collins, S. Grissom, B. R. Zeeberg, W. Reinhold, J. N. Weinstein, et al. Analysis of ATP-Binding Cassette Transporter Expression in Drug-Selected Cell Lines by a Microarray Dedicated to Multidrug Resistance Mol. Pharmacol., December 1, 2004; 66(6): 1397 - 1405. [Abstract] [Full Text] [PDF]

				O. Sordet, Q. A. Khan, I. Plo, P. Pourquier, Y. Urasaki, A. Yoshida, S. Antony, G. Kohlhagen, E. Solary, M. Saparbaev, et al. Apoptotic Topoisomerase I-DNA Complexes Induced by Staurosporine-mediated Oxygen Radicals J. Biol. Chem., November 26, 2004; 279(48): 50499 - 50504. [Abstract] [Full Text] [PDF]

				M. I. Aladjem, S. Pasa, S. Parodi, J. N. Weinstein, Y. Pommier, and K. W. Kohn Molecular Interaction Maps--A Diagrammatic Graphical Language for Bioregulatory Networks Sci. Signal., March 2, 2004; 2004(222): pe8 - pe8. [Abstract] [Full Text] [PDF]

				D. S. Sappal, A. K. McClendon, J. A. Fleming, V. Thoroddsen, K. Connolly, C. Reimer, R. K. Blackman, C. E. Bulawa, N. Osheroff, P. Charlton, et al. Biological characterization of MLN944: A potent DNA binding agent Mol. Cancer Ther., January 1, 2004; 3(1): 47 - 58. [Abstract] [Full Text]

				A. V. Roschke, G. Tonon, K. S. Gehlhaus, N. McTyre, K. J. Bussey, S. Lababidi, D. A. Scudiero, J. N. Weinstein, and I. R. Kirsch Karyotypic Complexity of the NCI-60 Drug-Screening Panel Cancer Res., December 15, 2003; 63(24): 8634 - 8647. [Abstract] [Full Text] [PDF]

				H. Kim, G.-L. Xu, A. C. Borczuk, S. Busch, J. Filmus, M. Capurro, J. S. Brody, J. Lange, J. M. D'Armiento, P. B. Rothman, et al. The Heparan Sulfate Proteoglycan GPC3 Is a Potential Lung Tumor Suppressor Am. J. Respir. Cell Mol. Biol., December 1, 2003; 29(6): 694 - 701. [Abstract] [Full Text] [PDF]

				L. A. Hazlehurst, S. A. Enkemann, C. A. Beam, R. F. Argilagos, J. Painter, K. H. Shain, S. Saporta, D. Boulware, L. Moscinski, M. Alsina, et al. Genotypic and Phenotypic Comparisons of de Novo and Acquired Melphalan Resistance in an Isogenic Multiple Myeloma Cell Line Model Cancer Res., November 15, 2003; 63(22): 7900 - 7906. [Abstract] [Full Text] [PDF]